• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Applied DNA Sciences Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    6/17/25 4:15:04 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary
    Get the next $APDN alert in real time by email
    false 0000744452 0000744452 2025-06-16 2025-06-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): June 16, 2025

      

    Applied DNA Sciences, Inc.

    (Exact name of registrant as specified in its charter)

      

    Delaware

    (State or other jurisdiction

    of incorporation)

    001-36745

    (Commission File Number)

    59-2262718

    (IRS Employer

    Identification No.)

     

    50 Health Sciences Drive

    Stony Brook, New York 11790

    (Address of principal executive offices; zip code)

      

    Registrant’s telephone number, including area code:  

    631-240-8800

     

    N/A

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company  ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, $0.001 par value   APDN   The Nasdaq Stock Market

      

     

     

     

     

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On June 16, 2025, Dr. James A. Hayward informed Applied DNA Sciences, Inc. (the “Company”) of his intention to retire from the Company and that he will step down from his positions as Chief Executive Officer, member of the Company’s board of directors (the “Board”) and Chairman of the Board effective June 18, 2025. Dr. Hayward’s resignation is not the result of any dispute or disagreement with the Company or the Board on any matter relating to the Company’s operations, policies or practices.

     

    In connection with Dr. Hayward’s retirement, Dr. Hayward and the Company entered into a separation agreement dated June 16, 2025 (the “Separation Agreement”), pursuant to which the Company shall pay to Dr. Hayward, contingent upon his compliance with the terms of the Separation Agreement, the total gross amount of $450,000 to be paid over a period of eight months from the date of first payment, with the first installment being paid on or before July 15, 2025. The Separation Agreement also provides for a customary general release of claims in favor of the Company and customary post-employment covenants, including with respect to confidentiality and non-disparagement.

     

    The foregoing summary of the Separation Agreement is qualified in its entirety by reference to the full text of the Separation Agreement, which is filed as Exhibit 10.1 hereto and incorporated herein by reference.

     

    On June 17, 2025, the Board elected Judith Murrah, the Company’s current President, as Chief Executive Officer and as Chairperson and a member of the Board effective June 18, 2025.

     

    Ms. Murrah, age 67, has served as the Company’s Chief Operating Officer since January 19, 2021, Chief Information Officer since June 1, 2013, Secretary since December 22, 2017 and President since December 13, 2024. Before joining the Company, Ms. Murrah was the Senior Director of Information Technology at Motorola Solutions, which had acquired her former firm, Symbol Technologies. Her role at Motorola Solutions included overseeing the global IT program management office, financial and supplier operations and quality assurance. At Symbol Technologies, Ms. Murrah held leadership positions in product line management, global account sales, corporate and marketing communications and IT. Ms. Murrah holds an MBA from Harvard Business School and a B.S. in Industrial Engineering from the University of Rhode Island. She is an inventor on 14 U.S. patents. Ms. Murrah is active in Long Island’s business and academic community. She has co-founded and volunteers with non-profits engaging students in science, technology, engineering and math disciplines. She serves on the boards of the Middle Country Library Foundation, the Tesla Science Center at Wardenclyffe, and Stony Brook University’s Center for Corporate Education. Ms. Murrah was named to the Top 50 Women of Long Island Hall of Fame in 2023 and received the inaugural 2001 Diamond Award for Long Island Women Leaders in Technology.

      

    For serving as the Company’s Chief Executive Officer and Chairperson, Ms. Murrah’s compensation paid by the Company will continue at its current amount, with an annual base salary of $400,000. She will not receive any additional compensation for serving as a member of the Board.

     

    There are no arrangements or understandings between Ms. Murrah and any other persons pursuant to which she was elected as an officer or director. Ms. Murrah does not have any family relationships with any of the Company’s directors or executive officers. There are no transactions involving the Company and Ms. Murrah that the Company would be required to report pursuant to Item 404(a) of Regulation S-K.

     

    Item 7.01 Regulation FD Disclosure.

     

    On June 17, 2025, the Company issued a press release announcing the retirement of Dr. Hayward and the election of Ms. Murrah as Chief Executive Officer, director and Chairperson. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

     

    The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

     

     

     

     

    Item 9.01 Financial Statements and Exhibits. 

     

    (d) Exhibits.

     

    Exhibit No. Description
    10.1 Separation Agreement, dated June 16, 2025, by and between the Company and Dr. James A. Hayward.
    99.1 Press Release, dated June 17, 2025.
    104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: June 17, 2025 APPLIED DNA SCIENCES, INC.
         
      By: /s/ Beth Jantzen
      Name: Beth Jantzen
      Title: Chief Financial Officer

     

     

     

     

    Get the next $APDN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $APDN

    DatePrice TargetRatingAnalyst
    2/11/2022$8.00 → $6.00Buy
    HC Wainwright & Co.
    8/13/2021$13.00 → $11.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $APDN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Applied DNA Sciences with a new price target

      HC Wainwright & Co. reiterated coverage of Applied DNA Sciences with a rating of Buy and set a new price target of $6.00 from $8.00 previously

      2/11/22 6:29:21 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • HC Wainwright & Co. reiterated coverage on Applied DNA Sciences with a new price target

      HC Wainwright & Co. reiterated coverage of Applied DNA Sciences with a rating of Buy and set a new price target of $11.00 from $13.00 previously

      8/13/21 6:30:16 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • HC Wainwright & Co. reiterated coverage on Applied DNA Sciences with a new price target

      HC Wainwright & Co. reiterated coverage of Applied DNA Sciences with a rating of Buy and set a new price target of $13.00 from $14.00 previously

      4/22/21 6:37:35 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary

    $APDN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates

      - Signals Start of New Commercialization Phase for LineaRx Subsidiary -- Company Negotiating GMP Supply Agreement -- Company Reaffirms Strategic Restructuring Timeline - STONY BROOK, NY / ACCESSWIRE / January 10, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the completion of the buildout of its new Good Manufacturing Practices (GMP) manufacturing facility (the "facility") within its Stony Brook, New York, headquarters and readiness to accept orders for the manufacture of LineaDNA™ IVT templates that clients can utilize for the production of mRNA clinical trial materials. The facility is undergoing fi

      1/10/25 9:00:00 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • Applied DNA Reschedules Investor Update Call in Observance of the National Day of Mourning in Recognition of the Passing of Former President Jimmy Carter

      STONY BROOK, NY / ACCESSWIRE / January 8, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it has rescheduled its Investor Update call to Thursday, February 13, 2025, to coincide with the release of its first quarter fiscal 2025 financial results.The Company originally scheduled an Investor Update call for January 9, 2025, to update shareholders on its strategic restructuring announced in December 2024 and GMP initiative. The change reflects the observance of the National Day of Mourning in recognition of the passing of former President Jimmy Carter.About Applied DNA Sciences

      1/8/25 4:30:00 PM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA

      - Regulatory Approval Showcases Clinical Advancement of Linea DNA™ as a Rapid and Effective Means of Producing CAR-T cell Therapies -STONY BROOK, NY / ACCESSWIRE / December 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, announced that the State Institute for Drug Control of the Czech Republic (SÚKL) approved an application for a Phase I clinical trial of an investigational CD123-specific autologous CAR T-cell therapy by the Institute of Hematology and Blood Transfusion (ÚHKT/Eng: IHBT) in Prague for the treatment of relapsed and/or refractory acute myeloid leukemia (AML). UHKT-CAR123-01 utilizes Applied DNA's synt

      12/18/24 9:00:00 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary

    $APDN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Jantzen Beth

      4 - APPLIED DNA SCIENCES INC (0000744452) (Issuer)

      3/27/23 9:30:56 PM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • SEC Form 4 filed by Shorrock Clay

      4 - APPLIED DNA SCIENCES INC (0000744452) (Issuer)

      3/27/23 9:30:40 PM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • SEC Form 4 filed by Murrah Judith

      4 - APPLIED DNA SCIENCES INC (0000744452) (Issuer)

      3/27/23 9:30:30 PM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary

    $APDN
    SEC Filings

    See more
    • Applied DNA Sciences Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - APPLIED DNA SCIENCES INC (0000744452) (Filer)

      6/30/25 4:05:52 PM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • Applied DNA Sciences Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - APPLIED DNA SCIENCES INC (0000744452) (Filer)

      6/17/25 4:15:04 PM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • Applied DNA Sciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - APPLIED DNA SCIENCES INC (0000744452) (Filer)

      6/6/25 2:28:36 PM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary

    $APDN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Applied DNA Sciences Inc.

      SC 13G - APPLIED DNA SCIENCES INC (0000744452) (Subject)

      11/14/24 5:46:25 PM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by Applied DNA Sciences Inc.

      SC 13G/A - APPLIED DNA SCIENCES INC (0000744452) (Subject)

      11/13/24 4:15:25 PM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by Applied DNA Sciences Inc.

      SC 13G/A - APPLIED DNA SCIENCES INC (0000744452) (Subject)

      11/7/24 10:11:34 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary

    $APDN
    Leadership Updates

    Live Leadership Updates

    See more
    • Applied DNA Advances Commercialization of Linea(TM) IVT Platform, Appoints Beverly Wolgast as Executive Director of Quality and cGMP Programs

      Experienced Biopharma/Pharmaceutical Executive to Lead Implementation of cGMP-quality LineaDNA™ Capability for IVT mRNA ProductionPreviously Led Manufacturing Operations Scale-up for the BioNTech/Pfizer mRNA COVID-19 Vaccine at CDMO Division of Maravai LifeSciencesSTONY BROOK, NY / ACCESSWIRE / September 6, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the appointment of Beverly Wolgast, Ph.D., as executive director of Quality and cGMP Programs. Dr. Wolgast will oversee and manage Applied DNA's quality assurance and control and regulatory compliance spanning the Company's three business segments, incl

      9/6/23 9:00:00 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • Applied DNA Appoints Clay Shorrock as Chief Legal Officer and Executive Director of Business Development

      STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that Clay Shorrock, J.D., has rejoined the Company effective immediately to serve on the executive leadership team as Chief Legal Officer and Executive Director, Business Development. In this newly created role, Mr. Shorrock will lead Applied DNA’s legal, regulatory, IP, and business development functions. Dr. James A. Hayward, president and CEO, Applied DNA, said, “As we continue to advance the adoption of our PCR-based, LinearDNATM manufacturing platform across highly regulated markets and further devel

      4/1/21 8:00:00 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary

    $APDN
    Financials

    Live finance-specific insights

    See more
    • Applied DNA to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GMP Manufacturing Facility Build-out

      STONY BROOK, NY / ACCESSWIRE / December 16, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its fourth quarter and fiscal year 2024 financial results after the market close on Tuesday, December 17, 2024.The Company will host a conference call for the investment community to coincide with an update on its GMP manufacturing facility build-out on Thursday, January 9, 2025, at 4:30 p.m. ET.Webcast and Conference Call Date & Time: Thursday, January 9 @ 4:30 p.m. ETDial In:Domestic callers (toll free): 844-887-9402International callers: 412-317-6798Canadian callers

      12/16/24 10:00:00 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • Applied DNA to Report Third Quarter Fiscal 2024 Financial Results on Thursday, August 8, 2024

      STONY BROOK, NY / ACCESSWIRE / August 7, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its third quarter fiscal 2024 financial results after market close on Thursday, August 8, 2024. In conjunction with this announcement, Applied DNA management will host a conference call for analysts and members of the investment community starting at 4:30 p.m. ET the same day. On this call, management will discuss the Company's financial results and recent accomplishments.Date & Time: Thursday, August 8 @ 4:30 p.m. ETDial In:Domestic callers (toll free): 844-887-9402Inter

      8/7/24 8:00:00 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • Applied DNA Announces Second Quarter Fiscal Year 2024 Financial Results

      STONY BROOK, NY / ACCESSWIRE / May 10, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced consolidated financial results for its second fiscal quarter ended March 31, 2024. The Company's Form 10-Q can be viewed at https://investors.adnas.com/sec-filings/. The Company will not host a financial webcast or call for this most recent quarterly reporting period. The Company will host an investor update call on June 12, 2024.Summary Second Quarter Fiscal 2024 Financial Results:Total revenues were approximately $930 thousand for the three-month period March 31, 2024, compared to $4.4 million for the second quarter

      5/10/24 4:05:00 PM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary